Abbott Labs stock price target raised to $158 from $154 at UBS

Investing.com - UBS raised its price target on Abbott Labs (NYSE:ABT) to $158.00 from $154.00 on Friday, while maintaining a Buy rating on the healthcare company’s stock. Currently trading at $127.47, InvestingPro analysis suggests Abbott is undervalued, with analysts’ targets ranging up to $162.

The firm highlighted the sustainability of Abbott’s double-digit MedTech sales growth as the most significant takeaway from the company’s third-quarter 2025 earnings report, expecting this strong performance to continue. With overall revenue growth of 6.37% and a P/E ratio of 15.95, Abbott demonstrates strong financial execution, maintaining a GREAT financial health score according to InvestingPro metrics.

UBS noted potential upside to Wall Street’s 2026 estimates for Abbott, which management effectively endorsed during the recent earnings call, creating what the firm described as an attractive buying opportunity.

The analysis acknowledged weakness in Abbott’s non-MedTech segments, which, combined with high expectations heading into the quarter, led to some market disappointment.

UBS expects Abbott’s Diagnostics segment to benefit from easier comparisons in 2026, while U.S. Pediatric Nutrition should return to low-single-digit growth after a WIC contract loss, which will be offset by two newly awarded WIC contracts taking effect in the first half of 2026.

In other recent news, Abbott Laboratories reported its third-quarter earnings, with sales reaching $11.37 billion, closely aligning with consensus estimates. The company experienced a notable 7.5% organic growth, excluding COVID testing. Abbott’s Medical Devices portfolio stood out, with significant growth in Diabetes Care, Electrophysiology, CRM, and Structural Heart segments. UBS, Benchmark, and RBC Capital all reiterated their positive ratings on Abbott, highlighting the strength in MedTech and device sales despite some mixed results. UBS maintained a Buy rating with a price target of $154, emphasizing the sustainability of MedTech growth. Benchmark also reiterated a Buy rating, setting a price target of $145, while RBC Capital maintained an Outperform rating with a $147 target. Wells Fargo and Jefferies both raised their price targets to $146, citing the strength in Abbott’s medical device growth and its robust pipeline. These developments reflect a continued positive outlook from analysts on Abbott’s performance and growth potential in the medical technology sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.